Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 14;2012(3):CD008372.
doi: 10.1002/14651858.CD008372.pub2.

Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents

Romy Hurwitz  1 , Roger Blackmore, Philip Hazell, Katrina Williams, Susan Woolfenden
Affiliations

Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents

Romy Hurwitz et al. Cochrane Database Syst Rev. .

Abstract

Background: Autism spectrum disorders (ASD) are a heterogeneous group of neurodevelopmental disorders, ranging in severity and characterised by early onset of delay and deviance in the development of social interaction, and verbal and nonverbal communication. ASD is associated with restricted and/or stereotyped interests or behaviours. Tricyclic antidepressants (TCAs) block noradrenaline and serotonin reuptake, increasing the availability of these neurotransmitters in the central nervous system. Via their impact on serotonin, TCAs have been used in the treatment of autistic symptoms and comorbidities in individuals with ASD.

Objectives: To determine if treatment with tricyclic antidepressants:1) improves the core features of autism, including restricted social interaction, restricted communication, and stereotypical and repetitive behaviours; 2) improves non-core features such as challenging behaviours; 3) improves comorbid states, such as depression and anxiety; 4) causes adverse effects.

Search methods: We ran the latest searches for this review on 23 May 2011. We searched: Cochrane Central Register of Controlled Trials (CENTRAL), 2011 Issue 2, MEDLINE (1948 to May Week 2, 2011), EMBASE (1980 to 2011 Week 2), PsycINFO (1887 to current), CINAHL (1937 to current). We also searched Dissertation Abstracts International via Dissertation Express, and the metaRegister of Controlled Trials.

Selection criteria: Randomised controlled trials of any dose, duration and frequency of oral TCAs compared with placebo, in children and adolescents with a diagnosis of ASD, where at least one standardised outcome measure had been used.

Data collection and analysis: Two review authors independently selected and appraised the studies for inclusion and risk of bias. All data were continuous.

Main results: Three studies met the inclusion criteria for this review. Two studies used clomipramine and one used tianeptine. All three trials were small, with between 12 and 32 participants. One of the clomipramine trials involved children and young adults, while the other two trials enrolled only children. Due to heterogeneity in study participant characteristics, the TCA medications investigated and the outcome measures used, we were not able to perform any meta-analysis.In only one of the three studies was there any indication that giving children tianeptine could be effective in the short term. In this study, parents and teachers reported that it reduced irritability, hyperactivity, inadequate eye contact and inappropriate speech, but clinician ratings found no significant impact on these symptoms. There were also significant adverse effects, including increased drowsiness and reduced activity levels in these individuals while being treated with tianeptine. The evidence of the impact of clomipramine in the two studies is contradictory. There was evidence of improvement in autistic symptoms, irritability and obsessive-compulsive disorder type symptoms, but conflicting evidence in relation to hyperactivity across the two studies, and no significant changes found with inappropriate speech. There were also adverse effects reported with the use of clomipramine. Although side effect ratings were not significantly different to placebo, there were significant dropout rates in the clomipramine arm of one study.

Authors' conclusions: Clinicians considering the use of TCAs need to be aware of the limited and conflicting evidence of effect and the side effect profile when discussing this treatment option with people who have ASD and their carers. Further research is required before TCAs can be recommended for treatment of individuals with ASD.

PubMed Disclaimer

Conflict of interest statement

  1. Romy Hurwitz ‐ none known.

  2. Roger Blackmore ‐ none known.

  3. Philip Hazell ‐ has worked as a consultant for Eli Lilly and Janssen. He has research contracts with Eli Lilly and Celltech. He is a member of the advisory board of Eli Lilly, Australia; Janssen, Australia; Novartis, Australia and Shire, International. Dr Hazell has given presentations for Eli Lilly, Pfizer, Janssen and Sanofi. He is an investigator in a trial of fluoxetine for autism spectrum disorders.

  4. Katrina Williams ‐ I gave a talk about treatments for autism at a symposium organised by Janssen‐Cilag Pty Ltd. Janssen‐Cilag had no control over the contents of the talk and the speaker's fee was paid to the University that employs me. I have no ongoing relationship with Janssen‐Cilag

  5. Susan Woolfenden ‐ none known.

Figures

1
1
Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.
2
2
Risk of bias summary: review authors' judgments about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD008372

References

References to studies included in this review

Gordon 1993 {published data only}
    1. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double‐blind comparison of clomipramine, desipramine and placebo in the treatment of Autistic Disorder. Archives of General Psychiatry 1993;50(6):441‐7. - PubMed
Niederhofer 2003 {published data only}
    1. Niederhofer H, Staffen W, Mair A. Tianeptine: A novel strategy of psychopharmacological treatment of children with autistic disorder. Human Psychopharmacology 2003;18(5):389‐93. - PubMed
Remington 2001 {published data only}
    1. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double‐blind, placebo‐controlled, crossover study. Journal of Clinical Psychopharmacology 2001;21(4):440‐4. - PubMed

References to studies excluded from this review

Aman 1986 {published data only}
    1. Aman MG, White AJ, Vaithianathan C, Teehan CJ. Preliminary study of imipramine in profoundly retarded residents. Journal of Autism and Developmental Disorders 1986;16(3):263‐73. - PubMed
Brasic 1994 {published data only}
    1. Brasic JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 1994;44(7):1309‐12. - PubMed
Brasic 1997 {published data only}
    1. Brasic JR, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. Journal of the Americam Academy of Child and Adolescent Psychiatry 1997;36(9):1165‐6. - PubMed
Brodkin 1997 {published data only}
    1. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: A prospective open‐label investigation. Journal of Child and Adolescent Psychopharmacology 1997;7(2):109‐21. - PubMed
Campbell 1971 {published data only}
    1. Campbell M, Fish B, Shapiro T, Floyd A. Imipramine in preschool autistic and schizophrenic children. Journal of Autism and Childhood Schizophrenia 1971;1(3):267‐82. - PubMed
Gordon 1992 {published data only}
    1. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB. Differential response of seven subjects with Autistic Disorder to clomipramine and desipramine. American Journal of Psychiatry 1992;149(3):363‐6. - PubMed
Jaselskis 1992 {published data only}
    1. Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with Autistic Disorder. Journal of Clinical Psychopharmacology 1992;12(5):322‐7. - PubMed
Kehrer 1978 {published data only}
    1. Kehrer HE. Infantile autism and drug therapy [German] [Die medikamentose Behandlung des kindlichen Autismus]. Bibliotheca Psychiatrica 1978;157:91‐7. - PubMed
Kurtis 1966 {published data only}
    1. Kurtis LB. Clinical study of the response to nortriptyline on autistic children. International Journal of Neuropsychiatry 1966;2(4):298‐301. - PubMed
Magen 1993 {published data only}
    1. Magen J. Negative results with clomipramine [comment]. Journal of the American Academy of Child and Adolescent Psychiatry 1993;32(5):1079‐80. - PubMed
McDougle 1992 {published data only}
    1. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward‐O'Brien D, Nielson J, et al. Clomipramine in autism: Preliminary evidence of efficacy. Journal of the American Academy of Child and Adolescent Psychiatry 1992;31(4):746‐50. - PubMed
Oesterheld 1997 {published data only}
    1. Oesterheld J, Kallepalli BR. Grapefruit juice and clomipramine: Shifting metabolic ratios. Journal of Clinical Psychopharmacology 1997;17(1):62‐3. - PubMed
Sanchez 1995 {published data only}
    1. Sanchez LE, Campbell M, Small AM, Adams PB, Uysal S, Hallin A. A comparison of live and videotaped ratings: Clomipramine and haloperidol in autism. Psychopharmacology Bulletin 1995;31(2):371‐8. - PubMed
Sanchez 1996 {published data only}
    1. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB. A pilot study of clomipramine in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry 1996;35(4):537‐44. - PubMed
Sloman 1998 {published and unpublished data}
    1. Sloman L. Haloperidol versus clomipramine in Autistic Disorder. 151st Annual Meeting of the American Psychiatric Association. 1998 May‐June; Vol. 17.
Szabo 1994 {published data only}
    1. Szabo CP, Bracken C. Imipramine and Asperger's. Journal of the American Academy of Child and Adolescent Psychiatry 1994;33(3):431‐2. - PubMed
Szekely 1980 {published data only}
    1. Szekely GA, Caplan R, Rotman A. Platelet dopamine uptake in autistic and other psychotic children. Inhibition by imipramine. Progress in Neuro‐Psychopharmacology 1980;4(2):215‐8. - PubMed
Weizman 1987 {published data only}
    1. Weizman A, Gonen N, Tyano S, Rehavi M. Platelet [3H] imipramine binding in autism and schizophrenia. Psychopharmacology 1987;91(1):101‐3. - PubMed

Additional references

APA 2000
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Text Revision (DSM‐IV‐TR). 4th Edition. Washington DC: American Psychiatric Association, 2000.
Baird 2006
    1. Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SCAP). Lancet 2006;368(9531):210‐5. - PubMed
Billstedt 2007
    1. Billstedt E, Gillberg IC, Gillberg C. Autism in adults: symptom patterns and early childhood predictors. Use of the DISCO in a community sample followed from childhood. Journal of Child Psychology and Psychiatry 2007;48(11):1102‐10. - PubMed
Caronna 2008
    1. Caronna EB, Milunsky JM, Tager‐Flusberg H. Autism spectrum disorders: clinical and research frontiers. Archives of Disease in Childhood 2008;93:518‐23. - PubMed
Chakrabarti 2005
    1. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. American Journal of Psychiatry 2005;162:1133‐41. - PubMed
Cook 1996
    1. Cook EH, Leventhal BL. The serotonin system in autism. Current Opinion in Paediatrics 1996;8:348‐54. - PubMed
Findling 1999
    1. Findling RL, Reed MD, Blumer JL. Pharmacological treatment of depression in children and adolescents. Paediatric Drugs 1999;1:161‐82. - PubMed
Fombonne 1999
    1. Fombonne E. The epidemiology of autism: a review. Psychological Medicine 1999;29(4):769‐86. - PubMed
Fombonne 2005
    1. Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. Journal of Clinical Psychiatry 2005;66:3‐8. - PubMed
Guillem 2006
    1. Guillem P, Cans C, Guinchat V, Ratel M, Jouk PS. Trends, perinatal characteristics and medical conditions in pervasive developmental disorders. Developmental Medicine and Child Neurology 2006;48(11):896‐900. - PubMed
Higgins 2008
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org.
Howlin 2004
    1. Howlin P, Goode S, Hutton J, Rutter M. Adult outcomes for children with autism. Journal of Child Psychology and Psychiatry 2004;45:212‐29. - PubMed
Hranilovic 2007
    1. Hranilovic D, Busjas‐Petkovic Z, Vragovic R, Vuk T, Hock K, Jernej B. Hyperserotonemia in adults with autistic disorder. Journal of Autism and Developmental Disorders 2007;37(10):1934‐40. - PubMed
Joseph 2002
    1. Joseph RM, Tager‐Flusberg H, Lord C. Cognitive profiles and social‐communicative functioning in children with autism spectrum disorder. Journal of Child Psychology and Psychiatry 2002;43(6):807‐21. - PMC - PubMed
Nishiyama 2009
    1. Nishiyama T, Taniai H, Miyachi T, Ozaki K, Tomita M, Sumi S. Genetic correlation between autistic traits and IQ in a population‐based sample of twins with autism spectrum disorders (ASDs). Journal of Human Genetics 2009;54:56‐61. - PubMed
Peretti 2000
    1. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants versus serotonin reuptake inhibitors. Review. Acta Psychiatrica Scandinavica. Supplementum 2000;101(403):17‐25. - PubMed
Posey 2001
    1. Posey DJ, McDougle CJ. Pharmacotherapeutic management of autism. Expert Opinion of Pharmacotherapy 2001;2(4):587‐685. - PubMed
Potter 1998
    1. Potter WZ, Manji HK, Rudorfer MW. Tricyclics and tetracyclics. The American Psychiatric Press Textbook of Psychopharmacology. 2nd Edition. Washington, DC: American Psychiatric Press, 1998:199‐218.
RevMan 2008 [Computer program]
    1. The Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2008.
Sadock 2005
    1. Sadock BJ, Sadock VA. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 8th Edition. Lippincott Williams and Wilkins, 2005.
Volkmar 2004
    1. Volkmar FR, Lord C, Bailey A, Schultz RT, Klin A. Autism and Pervasive Developmental Disorders. Journal of Child Psychology and Psychiatry 2004;45(1):135‐70. - PubMed
WHO 1993
    1. World Health Organization. The ICD‐10 classification of mental and behaviour disorders: diagnostic criteria for research. Geneva: World Health Organization 1993.
Williams 2006
    1. Williams JG, Higgins JPT, Brayne CEG. Systematic review of prevalence of autism spectrum disorders. Archives of Disease in Childhood 2006;91:8‐15. - PMC - PubMed
Williams 2010
    1. Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI: 10.1002/14651858.CD004677.pub2] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources